Issue Date: June 20, 2016
Dr. Reddy’s picks up Teva portfolio
The Indian generic drugmaker Dr. Reddy’s Laboratories has agreed to acquire eight Abbreviated New Drug Applications from Israel’s Teva Pharmaceutical Industries for $350 million. Teva is divesting the products as a precondition to closing on its acquisition of Allergan’s generic drugs business. The combined annual U.S. sales of the branded versions of the drugs involved are about $3.5 billion, the firms say.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society